Soligenix

322 articles with Soligenix

• Soligenix Announces Completion of Enrollment and Preliminary Safety Results of a Phase 1B Clinical Trial for RiVax(TM)

  11/2/2010

• Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec(R) in the Prevention of Acute GVHD

  10/25/2010

• Soligenix Provides Corporate Update on Phase 3 Trials

  9/27/2010

• Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant

  8/23/2010

• Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments

  8/13/2010

• Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT

  6/29/2010

• Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax(TM) Administration

  6/25/2010

• Soligenix Announces Financing of $5.16 Million With Its Partner Sigma-Tau Pharmaceuticals and Other Institutional Investors

  6/16/2010

• Soligenix Announces Grant of European Patent for the Treatment of GVHD and Leukemia with Oral Beclomethasone Dipropionate

  6/3/2010

• Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate

  5/19/2010

• Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments

  5/17/2010

• Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial

  5/12/2010

• Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders

  5/10/2010

• Soligenix Reports Year-End 2009 Financial Results and Reviews Accomplishments

  4/1/2010

• Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology

  2/17/2010

• Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin

  12/28/2009

• Soligenix Reports Third Quarter 2009 Financial Results

  11/13/2009

• Soligenix to Present at 8th Annual Biotechnology Industry Organization (BIO) Investor Forum Presentation at 1PM PDT, Thursday, October 29, Available by Webcast

  10/28/2009

• Soligenix Announces Initiation of its Confirmatory Phase 3 Clinical Trial of orBec(R) in Acute GI GVHD

  10/15/2009

• Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors

  10/14/2009